Trials (Léon Bérard Center): Revision history

14 December 2025

• curprev 18:3418:34, 14 December 2025‎ Francine talk contribs‎ 158,645 bytes +266‎ No edit summary undo

6 December 2025

• curprev 12:4112:41, 6 December 2025‎ Lucas talk contribs‎ m 158,379 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:4220:42, 2 December 2025‎ Francine talk contribs‎ 156,678 bytes +7‎ No edit summary undo
• curprev 13:5913:59, 2 December 2025‎ Lucas talk contribs‎ m 156,671 bytes +22,583‎ Update categories. undo

6 November 2024

• curprev 15:5315:53, 6 November 2024‎ Victor talk contribs‎ 134,088 bytes +11‎ No edit summary undo

4 January 2024

• curprev 16:2616:26, 4 January 2024‎ Francine talk contribs‎ 134,077 bytes +2‎ No edit summary undo
• curprev 16:2016:20, 4 January 2024‎ Francine talk contribs‎ 134,075 bytes +19‎ No edit summary undo
• curprev 16:2016:20, 4 January 2024‎ Francine talk contribs‎ 134,056 bytes +19‎ No edit summary undo
• curprev 16:1916:19, 4 January 2024‎ Francine talk contribs‎ 134,037 bytes +2,447‎ No edit summary undo

1 December 2023

• curprev 21:5221:52, 1 December 2023‎ Francine talk contribs‎ 131,590 bytes +131,590‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Léon Bérard Center page '''NCTID''': NCT01222767 '''Title''': Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy '''Study Summary''': This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Loc..."